Almirall’s 2025 9M Results November 10, 2025 Almirall continues its sustained growth trajectory in 9M 2025 - delivering 12.8% net sales growth, strong dermatology performance, solid commercial execution in Europe, and further pipeline progress Sustained strong growth momentum with 12.8% Net Sales YoY increase to a total of €820.7 MM, with biologics continuing to deliver double-digit growth YoY and dermatology sales in Europe increasing 24.5% YoY further advancing Almirall´s leadership in medical dermatology. EBITDA increase of 27.1% YoY in line with expectations, reaching a total of €180.7 MM. On track to meet 2025 guidance driven by biologics growth and operational strength. Performance continues to be primarily driven by the biologics portfolio, with Ilumetri® net sales increasing 12.1% YoY (total of €170.9 MM), and Ebglyss® net sales of €75.5 MM – reflecting a more than 3x increase YoY as European markets are ramping up after launch. Solid performance of the broad dermatology product portfolio with Wynzora® growing 32.4% YoY to a total of €25.4 MM, and Klisyri® growing 22.6% YoY to a total of €20.1 MM, further enhancing Almirall’s position as trusted partner for patients and dermatologists. Continued R&D pipeline progress includes the start of the phase II study of the anti-IL-1RAP mAb, and plan to initiate three additional proof-of-concept studies over the coming 9 to 12 months.
Soho House & Co Inc. Announces Third Quarter 2025 Results November 7, 2025 Soho House & Co Inc. (NYSE: SHCO) (“SHCO,” “Company,” “we” or “our”), a global membership platform that connects a vibrant, diverse, and global group of members, today announced results for the third quarter ended September 28, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107045088/en/ Third Quarter 2025 Highlights Total revenues of [...]
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights November 6, 2025 Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine months of 2025, respectively; quarter-end cash and restricted cash position was $331.7 million Roche to initiate the Phase 3 PARAISO clinical trial evaluating prasinezumab, a potential first-in-class anti-alpha-synuclein antibody, for early-stage Parkinson's disease by end of 2025 Novo Nordisk initiated the Phase 3 CLEOPATTRA clinical trial evaluating coramitug, a potential first-in-class amyloid depleter, for ATTR amyloidosis with cardiomyopathy Novo Nordisk to present Phase 2 results for coramitug during a late-breaking session at the American Heart Association Scientific Sessions on November 10, 2025 Bristol Myers Squibb obtained Fast Track designation from the U.S. FDA for BMS-986446 (PRX005), an anti-MTBR-tau-targeting antibody, for the treatment of Alzheimer’s disease Prothena will convene an Extraordinary General Meeting on November 19, 2025 to obtain shareholder approval on a proposal reducing share capital to create distributable reserves to support a share redemption program to be conducted in 2026 if deemed appropriate Potential to earn up to $105 million in aggregate clinical milestone payments by end of 2026 related to the advancement of coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerative diseases by Bristol Myers Squibb
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights November 6, 2025 SANRECO Phase 2 study of divesiran in polycythemia vera (PV) fully enrolled; topline results anticipated in 3Q 2026 Strong balance sheet and cash runway into 2028
TITAN Group: Nine-Month 2025 Results November 6, 2025 Regulatory News: Titan SA (Euronext Brussels, ATHEX and Euronext Paris, TITC) announces the nine-month 2025 financial results. Record nine-month EBITDA profitability and a positive outlook Group Sales YTD increased by 1.4%, at €2,013m, thanks to the strong performance in Greece, in the US & in Egypt, driven by increased volumes and overall firm pricing levels. [...]
SES Delivers Solid 9 Months and Q3 2025 Results November 6, 2025 SES S.A. fully consolidates Intelsat from 17 July 2025 and announces financial results for the nine months and three months ended 30 September 2025 with solid operational and financial performance. Solid 9 months 2025 financial performance on a reported basis (Intelsat fully consolidated from 17 July 2025) Revenue of €1,747 million (+19.8% yoy(1)) and Adjusted [...]
IGI Reports Third Quarter and First Nine Months of 2025 Unaudited Financial Results November 4, 2025 International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today reported financial results for the third quarter and first nine months of 2025. Highlights for the third quarter and first nine months of 2025 include: (in millions of U.S. Dollars, except percentages and per share information) Quarter Ended September 30, Nine Months [...]
Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months November 4, 2025 Company accelerating commercialization readiness plans by 9-12 months, following completion of COMP006 trial enrollment and positive meeting with FDA on NDA submission strategies for COMP360 in TRD, including potential rolling submission Company now plans to disclose 9-week data (Part A) from COMP006 together with 26-week data (Part B) from COMP005 in Q1 2026 Disclosure of 26-week (Part B) COMP006 data expected in early Q3 2026 Cash position of $185.9 million as of September 30, 2025 Conference call on November 4 at 8 am ET (1 pm UK)
Algoma Central Corporation Reports Financial Results for the 2025 Third Quarter November 4, 2025 Milestone 100th vessel, continued fleet growth, new strategic partners, and strong core results define the quarter